BRIM Biotechnology announces first patient enrollment in pivotal Phase 3 clinical trial of BRM421 for Dry Eye Disease
Taipei, Taiwan, 2nd March 2023 / BRIM Biotechnology Inc. (“BRIM,” TPEx 6885), a clinical-stage biotechnology company advancing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases, announced today that the first patient has been enrolled in its Phase 3 clinical…
Novel regenerative peptide therapy for dry eye disease, BRM421, advances to Phase 3 clinical trials
There is currently no cure for Dry Eye Disease. Existing treatments are often not enough to control discomfort for moderate to severe patients unless there is a way to further speed up the healing process. Through its multi-modal mechanism of…
BRIM Biotechnology strengthens leadership team in preparation for transformational year ahead
BRIM’s new Board of Directors elects Andrew Lin as the new Chairman of the Board and appoints Dr. Wen-Chyi Shyu as the new CEO Taipei, Taiwan, February 20th, 2023 / BRIM Biotechnology, Inc. (BRIM, TPEx 6885), a clinical-stage company developing novel regenerative therapies…
BRIM Biotechnology receives FDA Orphan Drug Designation for BRM424 to treat neurotrophic keratitis
Taipei, Taiwan, 8th December 2022 / BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) is pleased to announce that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for BRM424 in the treatment of neurotrophic keratitis (NK), a rare degenerative eye…
BRIM Biotechnology, Inc. raises $20 million in Series E funding round
Taipei, Taiwan, 1st December 2022 / BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885), a clinical-stage biotechnology company advancing novel regenerative therapies to help combat and cure ophthalmology and degenerative joint diseases, announced today that it has raised $20 million in its Series E funding…
BRIM Biotech submits US Phase 3 clinical trial protocol for BRM421 in the treatment of dry eye disease to the FDA
Taipei, Taiwan, Nov 16th, 2022, BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) announced today that it has officially submitted the Phase 3 clinical trial protocol for BRM421 in the treatment of dry eye disease (DED) to the U.S. Food and Drug Administration…
BRIM Biotechnology receives FDA agreement on Phase 3 clinical trial design for BRM421, BRIM’s lead candidate for Dry Eye Disease, at End of Phase 2 Meeting
Taipei, Taiwan, 1st November, 2022 / BRIM Biotechnology, Inc. (“BRIM,” TPEx 6885) is pleased to announce that it has received agreement from the US Food and Drug Administration (FDA) on the Phase 3 clinical trial design for its lead candidate…

BRIM Biotechnology Board of Directors approves seasoned equity offering of USD 18 million to accelerate phase 3 development of lead asset BRM421 for dry eye syndrome
Taipei, Taiwan, August 12th, 2022/ BRIM Biotechnology, Inc. (BRIM, TPEx 6885) reports that the Company’s Board of Directors has approved a proposal for a seasoned equity offering, following its recent emerging stock market (ESM) listing, to increase capital and advance…

The road to regeneration: Could regenerative peptide therapy pave the way for new treatment methods for severe dry eye?
Severe dry eye disease (DED) affects the productivity and quality of life of millions of people. Prompted by the prevalence of this chronic condition, many pharmaceutical companies have set out in search of more robust treatments. Solutions have thus far…

BRIM Biotechnology enters Emerging Stock Market in Taiwan
Taipei, Taiwan, 23 rd June 2022 / BRIM Biotechnology, Inc. (BRIM, TPEx 6885) enters the Emerging Stock Market (ESM) in Taiwan on 23 rd June 2022, CST. The news was announced at the company’s first earnings call on 22 nd…